Whenever we have a new medicine, we always restart the clock in terms of safety. In a response to Scientific American s request for comment, the Eli Lilly spokesperson said that the FDA reviewed the companys robust clinical data package and that the approval establishes Foundayos strong safety and efficacy profile. Foundayo and other weight-loss drug candidates in the works could increase supply and help with affordability of GLP-1 drugs overallthough that might take some time, Horn says
Growth of telemedicine and digital prescribing platforms is enabling remote consultations and direct-to-home delivery of injectable treatments
For broader handling risk, read our research peptide safety guide
Staying upright for at least 30 minutes after eating keeps gravity working against reflux
Tirzepatide (Mounjaro/Zepbound) by Eli Lilly is the FDA-approved dual GIP/GLP-1 agonist that produces the greatest weight loss of any approved medication, but requires weekly injections
And while global spend- ing on obesity medications hit $24 billion last year, Ameri- can multinational company IQVIAs estimation is that it should reach $131 billion by 2028
